Clinical Trials Browser

Melanoma × talimogene laherparepvec × 1 year × Clear all

NCT02965716 2025-11-18

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Phase 2 Active not recruiting

43 enrolled 18 charts

Melanoma